Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
Chalmers University of Technology spin out takes a different route to cancer biomarker identification
Executive Summary
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
You may also be interested in...
Start-Up Spotlight: Pre Diagnostics Picks Up Momentum In Early Neurodegenerative Disease Detection
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Turkey’s Updated Medtech Advertising Regulations Will Assist Traceability
Device sales centers are being required to update the government’s product tracking system with sales data under a series of recent changes spurred partly by COVID-19.
UK Regulatory System Progress And New MedTech Directorate Unveiled At Industry Meeting
In the three months since Brexit, UK medtech stakeholders have seen the beginnings of new regulations, foreign trade plans being put in place, and perhaps new perceptions of medtech’s value.